A comparative study of the anticholinesterase activity of several antipsychotic agents

Pharmacology Biochemistry and Behavior

Volumn 75, Issue 4, 2003, Pages 895-901

  Nasello, Antonia G ^a   Gidali, Debora ^b   Felicio, Luciano F ^b  

^a Santa Casa de Sao Paulo School of Medicine   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Caudate putamen; Clozapine; Dopamine; Haloperidol; Rotational behavior

Indexed keywords

AMPHETAMINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; SULPIRIDE; THIORIDAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINESTERASE INHIBITION; CIRCLING BEHAVIOR; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVITY; FUNCTION TEST; IC 50; IN VITRO STUDY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ANIMALIA;

EID: 0142074885     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00185-0     Document Type: Article

References (40)

1. Acquas E., Fibiger H.C. Dopaminergic regulation of striatal acetylcholine release: the critical role of acetylcholinesterase inhibition. J. Neurochem. 70:1998;1088-1093.
2. Bekpinar S., Oner P., Eryurek F.G. Comparative effects of chronic administration of some psychotropic drugs on rat brain cortex acetylcholinesterase activity. Prog. Neuropsychopharmacol. Biol. Psychiatry. 8:1994;555-562.
3. Bymaster F.P., Felder C.C. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry. 7(Suppl. 1):2002;S57-S63.
4. Casas M., Prat G., Robledo P., Barbanoj M., Kulisevsky J., Jane F. Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats. Eur. J. Pharmacol. 366:1999;1-11.
5. Castello E., Boioli B., Dajas F. Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats. Pharmacol. Biochem. Behav. 41:1992;547-550.
6. Chemnitius J.M., Haselmeyer K.H., Gonska B.D., Kreuzer H., Zech R. Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol. Res. 34:1996;65-72.
7. Dajas-Bailador F., Costa G., Emmett S., Bonilla C., Dajas F. Acetylcholinesterase inhibitors block acetylcholine-evoked release of dopamine in rat striatum, in vivo. Brain Res. 722:1996;12-18.
8. Drago F., Bohus B., Van Ree J.M., Scapagnini U., De Wied D. Behavioral responses of long-term hyperprolactinaemic rats. Eur. J. Pharmacol. 79:1982;323-327.
9. Ellman L., Courtney K.D., Andres V. Jr., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
10. Gagnon L., Bédard P.J., Rioux L., Gaudin D., Martinoli M.G., Pelletier G.et al. Regional changes of striatal dopamine receptors following denervation by 6-hydroxydopamine and fetal mesencephalic grafts in the rat. Brain Res. 558:1991;251-263.
11. German D.C., Manaye K.F., Wu D., Hersh L.B., Zweig R.M. Mesopontine cholinergic and non-cholinergic neurons in schizophrenia. Neuroscience. 94:1999;33-38.
12. Giacobini E., Zhu X.D., Williams E., Sherman K.A. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology. 35:1996;205-211.
13. Gronier B., Rasmussen K. Activation of midbrain presumed dopaminergic neurons by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Br. J. Pharmacol. 124:1998;455-464.
14. Howerton T.C., Murphy M.R., Miller S.A., Hartgraves S.L. Differential sensitivity of CNS regions to acetylcholinesterase inhibition following chronic low-dose soman treatment in the rat. Psychopharmacology. 105:1991;400-406.
15. Hsieh B.H., Deng J.F., Ger J., Tsai W.J. Acetylcholinesterase inhibition and the extrapyramidal syndrome: a review of the neurotoxicity of organophosphate. Neurotoxicology. 22:2001;423-427.
16. Huff F.J., Reiter C.T., Rosen J., Peters J., Van Kammen D.P. No effect of haloperidol on cerebrospinal fluid acetylcholinesterase in patients with schizophrenia. Biol. Psychiatry. 24:1988;701-704.
17. Iwanaga Y., Miyashita N., Morikawa K., Mizumoto A., Kondo Y., Itoh Z. A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine. Gastroenterology. 99:1990;401-408.
18. Kane J.M., Aguglia E., Altamura A.C., Gutierrez J.L.A., Brunello N., Fleischhacker W.W.et al. Guidelines for depot antipsychotic treatment in schizophrenia. Neuropsychopharmacology. 8:1998;55-66.
19. King D.J. Drug treatment of the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol. 8:1998;33-42.
20. Klink R., De Kerchove D'exaerde A., Zoli M., Changeux J.P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J. Neurosci. 21:2001;1452-1463.
21. Korenovsky A., Laev H., Mukerjee S., Mahadek S. Quantitative analyses of plasma cholinesterase isozymes in haloperidol-treated rats. Biol. Psychiatry. 27:1990;871-883.
22. Lidow M.S., Williams G.V., Goldman-Rakic P.S. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol. Sci. 19:1998;136-140.
23. Mazumder B., Mukherjee S., Sen P.C. The chlorpromazine inhibition of transport ATPase and acetylcholinesterase activities in the microsomal membranes of rat in vitro and in vivo. Mol. Cell. Biochem. 95:1990;13-20.
24. Modai I., Schwartz B., Aizenberg D. Serum pseudocholinesterase in psychiatric patients. Biol. Psychiatry. 22:1987;1238-1242.
25. Moore S., Kenyon P. Atypical antipsychotics, clozapine and sulpiride do not antagonize amphetamine-induced stereotyped locomotion. Psychopharmacology. 114:1994;123-130.
26. Mueller K. Locomotor stereotypy is produced by methylphenidate and amfonelic acid and reduced by haloperidol but not clozapine or thioridazine. Pharmacol. Biochem. Behav. 45:1993;71-76.
27. Nasello A.G., Gidali D., De Sá-Rocha L.C., Felicio L.F. Differential effects of bromopride and domperidone on cholinesterase activity in rat tissues. Life Sci. 56:1995;151-156.
28. Peacock L., Solgaardt T., Lublin H., Gerlach J. Clozapine versus typical antipsychotics: a retro and prospective study of extrapyramidal side effects. Psychopharmacology. 124:1996;188-196.
29. Pellegrino L.J., Pellegrini A.S., Cushman A.J. A stereotaxic atlas of the rat brain. 2nd ed. 1986;32 Plenum, New York.
30. Pisani A., Bonsi P., Centonze D., Calabresi P., Bernardi G. Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. J. Neurosci. 20:2000;RC1-RC6.
31. Ramaswamy S., Regunathan S., Bapna J.S. Anticholinesterase activity of prolactin: correlation with analgesia. J. Pharm. Pharmacol. 40:1988;306-307.
32. Roman S., Vivas N.M., Badia A., Clos M.V. Interaction of a new potent anticholinesterasic compound (±) huprine X with muscarinic receptors in rat brain. Neurosci. Lett. 325:2002;103-106.
33. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
34. Shannon H.E., Hart J.C., Bymaster F.P., Calligaro D.O., DeLapp N.W., Mitch C.H.et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J. Pharmacol. Exp. Ther. 290:1999;901-907.
35. Soreq H., Seidman S. Acetylcholinesterase - new roles for an old actor. Nat. Rev. Neurosci. 2:2001;294-302.
36. Spinedi A., Pacini L., Limatola C., Luly P., Farias R.N. A study of human erythrocyte acetylcholinesterase inhibition by chlorpromazine. Biochem. J. 278:1991;461-463.
37. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
38. Ushijima I., Kawano M., Kaneyuki H., Suetsugi M., Usami K., Hirano H.et al. Dopaminergic and cholinergic interaction in cataleptic responses in mice. Pharmacol. Biochem. Behav. 58:1997;103-108.
39. Zhang W., Yamada M., Gomeza J., Basile A.S., Wess J. Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J. Neurosci. 22:2002;6347-6352.
40. Zhou F.M., Liang Y., Dani J.A. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat. Neurosci. 4:2001;1224-1229.